MA51288B1 - Analogues d'incrétine et leurs utilisations - Google Patents

Analogues d'incrétine et leurs utilisations

Info

Publication number
MA51288B1
MA51288B1 MA51288A MA51288A MA51288B1 MA 51288 B1 MA51288 B1 MA 51288B1 MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A MA 51288 B1 MA51288 B1 MA 51288B1
Authority
MA
Morocco
Prior art keywords
incretin analogs
activity
receptors
incretin
analogs
Prior art date
Application number
MA51288A
Other languages
English (en)
Other versions
MA51288A (fr
Inventor
Jorge Alsina-Fernandez
Lili Guo
Tamer Coskun
Hongchang Qu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA51288A publication Critical patent/MA51288A/fr
Publication of MA51288B1 publication Critical patent/MA51288B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

L'invention concerne des analogues d'incrétine qui ont une activité au niveau de chacun des récepteurs de GIP, GLP-1 et glucagon. Les analogues d'incrétine ont des caractéristiques structurales conduisant à une activité équilibrée et une durée d'action prolongée à chacun de ces récepteurs. L'invention concerne également des procédés de traitement de maladies telles que le diabète sucré, la dyslipidémie, la stéatose hépatique, le syndrome métabolique, la stéatohépatite non alcoolique et l'obésité.
MA51288A 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations MA51288B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
EP18830618.7A EP3727426B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations
PCT/US2018/065663 WO2019125938A1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA51288A MA51288A (fr) 2021-03-31
MA51288B1 true MA51288B1 (fr) 2026-02-27

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51288A MA51288B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Country Status (31)

Country Link
US (4) US11542313B2 (fr)
EP (2) EP4691555A2 (fr)
JP (3) JP6961838B2 (fr)
KR (2) KR102622642B1 (fr)
CN (1) CN111491658B (fr)
AR (1) AR113486A1 (fr)
AU (1) AU2018388962B2 (fr)
BR (1) BR112020010244A2 (fr)
CA (1) CA3084005C (fr)
CL (1) CL2020001635A1 (fr)
CO (1) CO2020006255A2 (fr)
CR (1) CR20200255A (fr)
DK (1) DK3727426T3 (fr)
DO (1) DOP2020000123A (fr)
EA (1) EA202091290A1 (fr)
EC (1) ECSP20032650A (fr)
FI (1) FI3727426T3 (fr)
IL (2) IL275468B1 (fr)
JO (1) JOP20200137B1 (fr)
LT (1) LT3727426T (fr)
MA (1) MA51288B1 (fr)
MX (2) MX2020006548A (fr)
MY (1) MY199143A (fr)
PE (2) PE20210162A1 (fr)
PH (1) PH12020551025A1 (fr)
PL (1) PL3727426T3 (fr)
PT (1) PT3727426T (fr)
SG (1) SG11202005606VA (fr)
TW (2) TWI744579B (fr)
UA (1) UA129012C2 (fr)
WO (1) WO2019125938A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
KR102779458B1 (ko) * 2018-11-12 2025-03-12 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
JP2022545200A (ja) * 2019-08-19 2022-10-26 イーライ リリー アンド カンパニー インクレチン類似体を作製する方法
JP7788376B2 (ja) * 2019-12-03 2025-12-18 アンタグ セラピューティクス エーピーエス 最適化されたｇｉｐペプチド類縁体
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
AU2021241257A1 (en) * 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited QD dosing of GIP receptor agonist peptide compounds and uses thereof
JP2023550594A (ja) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
EP4281464A4 (fr) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
TWI837615B (zh) 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
US20250129135A1 (en) * 2021-05-26 2025-04-24 The United Bio-Technology (Hengqin) Co., Ltd Multi-Agonist and Use Thereof
WO2022268029A1 (fr) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Agoniste triple pour récepteurs glp-1, gcg et gip
CA3223313A1 (fr) * 2021-06-23 2022-12-29 Eli Lilly And Company Methodes d'utilisation et compositions comprenant un analogue d'incretine
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023088140A1 (fr) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 Peptide agrafé et son utilisation
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
EP4580608A1 (fr) 2022-08-29 2025-07-09 Eli Lilly And Company Compositions pour administration orale
EP4596574A1 (fr) * 2022-09-28 2025-08-06 Sunshine Lake Pharma Co., Ltd. Agoniste du récepteur triple glp-1/gcg/gip et son utilisation
KR20250096895A (ko) 2022-10-05 2025-06-27 일라이 릴리 앤드 캄파니 인크레틴 합성을 위한 펩티드
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
PE20252287A1 (es) 2023-01-31 2025-09-18 Lilly Co Eli Agonistas del trirreceptor gip/glp1/gcg y usos de estos
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
CN121002051A (zh) * 2023-04-11 2025-11-21 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
KR20260022948A (ko) * 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
AR132977A1 (es) 2023-06-15 2025-08-13 Novo Nordisk As Formulaciones farmacéuticas que comprenden una ciclodextrina
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法
WO2025016303A1 (fr) 2023-07-14 2025-01-23 北京拓界生物医药科技有限公司 Triagoniste des récepteurs glp-1, gip et gcg et son utilisation
WO2025087353A1 (fr) * 2023-10-26 2025-05-01 齐鲁制药有限公司 Polypeptide présentant une activité multi-agoniste et son utilisation
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
WO2025162423A1 (fr) * 2024-02-02 2025-08-07 杭州先为达生物科技股份有限公司 Triagoniste pour glp-1r, gipr et gcgr
WO2025264785A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264776A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264809A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
CN119978101B (zh) * 2024-07-30 2025-10-10 四川普康药业有限公司 多肽化合物及其应用
CN119823233A (zh) * 2025-03-18 2025-04-15 杭州思诺达医药科技有限责任公司 瑞他鲁肽的合成方法及瑞他鲁肽
CN120189527A (zh) * 2025-05-27 2025-06-24 南方医科大学第三附属医院（广东省骨科研究院） 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途
CN120623312B (zh) * 2025-06-26 2026-01-23 乐普健糖药业(重庆)有限公司 Glp-1、gip、gcg三重受体激动剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0915282A2 (pt) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
JP2013517307A (ja) * 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ 心臓病の処置
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2707713A2 (fr) * 2011-05-10 2014-03-19 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (ru) * 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TWI669309B (zh) * 2015-06-22 2019-08-21 美商美國禮來大藥廠 升糖素及ｇｌｐ－１共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
PH12018501409B1 (en) 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3217027A1 (fr) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Élement de revetement large destine a entourer une tige d'ancrage
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
MA53378A (fr) * 2018-07-23 2021-06-02 Lilly Co Eli Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète
WO2020023386A1 (fr) * 2018-07-23 2020-01-30 Eli Lilly And Company Composés co-agonistes de gip/glp1
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
MX2022009149A (es) * 2020-01-23 2022-12-15 Lilly Co Eli Compuestos coagonistas de gip/glp1.
PE20252287A1 (es) * 2023-01-31 2025-09-18 Lilly Co Eli Agonistas del trirreceptor gip/glp1/gcg y usos de estos

Also Published As

Publication number Publication date
TWI809515B (zh) 2023-07-21
PE20251598A1 (es) 2025-06-16
KR102622642B1 (ko) 2024-01-10
PT3727426T (pt) 2026-02-03
CR20200255A (es) 2020-07-12
CN111491658B (zh) 2024-04-26
JP2021506955A (ja) 2021-02-22
JP6961838B2 (ja) 2021-11-05
BR112020010244A2 (pt) 2020-10-13
TWI744579B (zh) 2021-11-01
TW201938188A (zh) 2019-10-01
JP7658877B2 (ja) 2025-04-08
PL3727426T3 (pl) 2026-03-16
AU2018388962A1 (en) 2020-06-04
MA51288A (fr) 2021-03-31
AR113486A1 (es) 2020-05-06
US20250313605A1 (en) 2025-10-09
DK3727426T3 (da) 2026-02-02
CL2020001635A1 (es) 2020-10-16
CN111491658A (zh) 2020-08-04
AU2018388962B2 (en) 2020-11-19
JOP20200137A1 (ar) 2022-10-30
CO2020006255A2 (es) 2020-05-29
DOP2020000123A (es) 2020-08-31
US20250059251A1 (en) 2025-02-20
KR20220133304A (ko) 2022-10-04
LT3727426T (lt) 2026-02-10
US11542313B2 (en) 2023-01-03
TW202202518A (zh) 2022-01-16
US12371465B2 (en) 2025-07-29
MX2020006548A (es) 2020-09-14
US20200331980A1 (en) 2020-10-22
UA129012C2 (uk) 2024-12-25
WO2019125938A1 (fr) 2019-06-27
MX2024010201A (es) 2024-08-26
JP2022033724A (ja) 2022-03-02
EP3727426A1 (fr) 2020-10-28
EP3727426B1 (fr) 2025-11-26
CA3084005C (fr) 2024-01-02
NZ765277A (en) 2024-08-30
CA3084005A1 (fr) 2019-06-27
ECSP20032650A (es) 2020-07-31
IL275468A (en) 2020-08-31
IL325353A (en) 2026-02-01
EA202091290A1 (ru) 2020-09-10
SG11202005606VA (en) 2020-07-29
FI3727426T3 (fi) 2026-02-04
PH12020551025A1 (en) 2021-09-06
US20230203121A1 (en) 2023-06-29
IL275468B1 (en) 2026-01-01
MY199143A (en) 2023-10-17
KR20200088419A (ko) 2020-07-22
KR102444783B1 (ko) 2022-09-19
PE20210162A1 (es) 2021-01-26
US12365716B2 (en) 2025-07-22
JP2025093970A (ja) 2025-06-24
JOP20200137B1 (ar) 2024-04-18
EP4691555A2 (fr) 2026-02-11
TW202415675A (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
JOP20200137B1 (ar) نظائر إنكريتين واستخداماتها
JOP20200136B1 (ar) نظائر إنكريتين واستخداماتها
JOP20220153B1 (ar) نظائر الإنكرتين واستخداماتها
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016004907A (es) Analogos del glucagon.
MY176022A (en) Acylated glucagon analogues
MX380322B (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1).
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2017012864A (es) Analogo acilado del glucagon.